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Human pathogens impact patient health through a complex in-
terplay with the host, but models to study the role of host genetics
in this process are limited. Human induced pluripotent stem cells
(iPSCs) offer the ability to produce host-specific differentiated cells
and thus have the potential to transform the study of infectious
disease; however, no iPSC models of infectious disease have been
described. Here we report that hepatocyte-like cells derived from
iPSCs support the entire life cycle of hepatitis C virus, including
inflammatory responses to infection, enabling studies of how host
genetics impact viral pathogenesis.
host variation in disease | infectious disease model | personalized
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Human pathogens impact patient well-being through complexhost–pathogen interactions. Despite the importance of host
Results and Discussion
iPSC-Derived Hepatocyte-Like Cells Express HCV Host Factors. To test
the hypothesis that iPSC-derived differentiated cells are per-
missive to infection, we sought to model HCV infection (Fig. 1).
HCV infects human hepatocytes, and we recently demonstrated
the directed differentiation of human iPSCs into hepatocyte-like
cells (iHLCs) (14). iHLCs routinely demonstrate an expected
cobblestone morphology (Fig. 2A, Left), and more than 80%
express both albumin and hepatocyte nuclear factor 3β (HNF-
3β) (Fig. 2A, Right). In addition, iHLCs secrete liver-specific
serum proteins such as albumin and α-1-antitrypsin at levels 15%
and 50%, respectively, of those of primary human hepatocytes
maintained in long-term culture models (Fig. 2B, Lower) (15).
Here, we investigated whether iHLCs express host genes im-
portant for HCV infection (“host factors”), are capable of sup-
porting the HCV life cycle, and respond to infection with an
appropriate antiviral inflammatory response. We found that
iHLCs express known HCV host factors, including the liver-
specific microRNA-122 (miR-122) (Fig. 2B) and entry factors
[CD81, SRBI, CLDN1, and occludin (OCLN)] (Fig. 2 C and D);
analysis of iPSC and iHLC transcriptional microarrays (14)
confirmed that host factors previously identified in an shRNA
screen (16) were enriched in iHLCs and were expressed to
a greater extent in iHLCs than iPSCs (Fig. 2E and Dataset S1).
Although iHLCs exhibit many characteristics of adult hep-
atocytes, their expression of phase-1 and phase-2 enzymes [high
expression of cytochrome P450, family 3, subfamily A, poly-
peptide 7 (CYP3A7); cytochrome P450, family 7, subfamily A,
polypeptide 1 (CYP7A1) ; and glutathione S-transferase α4
(GSTA4) and low expression of cytochrome P450, family 2,
subfamily C (CYP2C) family genes and cytochrome P450, family
3, subfamily A, polypeptide 4 (CYP3A4)] and coexpression of
α-fetoprotein and albumin is collectively more consistent with
the characteristics of a fetal hepatocyte (14, 17, 18). Experi-
mental evidence suggests that iPSCs are fully capable of dif-
ferentiating into terminally differentiated adult hepatocytes,
as demonstrated in mouse IPS tetraploid complementation ex-
periments and in mouse and human iHLC transplantation
experiments (14); however, culture conditions have not yet been
established that allow terminal differentiation, as indicated by
loss of α-fetoprotein expression and fetal cytochrome P450
expression.
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genetics in this interplay, in vitro model systems for studying the 
role of host genetic variation in infection often are unavailable 
because of tissue scarcity and challenges in primary culture. The 
discovery of cellular reprogramming and the ability to generate 
host- and tissue-specific cells from induced pluripotent stem 
cells (iPSCs) have the potential to transform the study of 
development, infectious disease, and degenerative disorders (1, 
2). For example, iPSCs have been used for the mechanistic study 
of a variety of cells types implicated in a wide diversity of disease 
(e.g., Friedreich ataxia, long-QT syndrome, Leopard syndrome,
Rett syndrome, and α-1-antitrypsin disease) (3–7). However, no 
iPSC models of any infectious disease have been reported to 
date. In this study, we describe the use of iPSC-derived cells as 
a model system for studying host–pathogen interactions for the 
hepatitis C virus (HCV).
Afflicting more than 170 million people worldwide, HCV is 
a prototypic pathogen for which host genetic factors have been 
implicated in modulating disease natural history and treatment 
response but whose functions remain poorly understood be-
cause of the lack of robust experimental systems. For example, 
genome-wide association studies have identified host poly-
morphisms in the IL-28B locus that correlate with spontaneous 
HCV clearance and viral response to IFN-based therapy (8). 
However, the functional consequences of these well-described 
polymorphisms remain elusive. Additionally, individuals with 
mutations in genes that are critical for HCV entry [e.g., low-
density lipoprotein receptor, CD81, scavenger receptor, class B, 
type 1 (SRBI), occludin (OCLN), claudin 1 (CLDN1)], assembly 
(apoliprotein E or apoliprotein B), or immune response (signal 
transducers and activators of transcription 1) have been de-
scribed (8–13). Despite our awareness that host genetics impacts 
viral pathogenesis in such individuals, the mechanistic basis for 
these correlations remains unclear largely because of the lack of 
a robust experimental system incorporating host cells with these 
genetic backgrounds. The development of an iPSC-derived HCV 
model has the potential to elucidate further the role of these host 
factors in disease pathogenesis.
iHLCs carried infection to Huh7.5s. Thus, iHLCs support the
complete HCV life cycle, including replication and release of
infectious virions. Therefore, iHLCs sustain the entire HCV viral
life cycle of at least genotype 2a, in accordance with prior reports
showing that human fetal hepatocytes are capable of sustaining
the HCV life cycle (22, 23). Future work toward a fully per-
sonalized in vitro model of HCV infection would incorporate
both personalized hepatocyte-like cells and isolates from HCV
patients, including the most common HCV genotype in the
United States, genotype 1a.
HCV Infection Induces an Antiviral Inflammatory Response from
iHLCs. We next determined whether infection induces an antivi-
ral inflammatory response, which is central to the natural history
of clinical disease progression but defective in existing in vitro
models of HCV (24). qRT-PCR on iHLC lysates 2 or 14 dpi
revealed that expression of inflammatory markers was up-regu-
lated by infection (Fig. 4A), and ELISA on culture supernatants
14 dpi verified persistent TNF-α secretion as a result of infection
(Fig. 4B). These results are characteristic of an ongoing in-
flammatory response in cells with an intact innate immune axis.
Notably, IL-28B, whose gene variation predicts response to
hepatitis C treatment in genome-wide association studies (8),
was expressed in response to viral infection 2 dpi but declined
over 2 wk, underscoring the potential for such a platform to
provide clinically relevant biological insights.
Existing model systems to study host genetics, such as poly-
morphisms in IL-28B, are limited to needle biopsies, surgical
resection, organ donation, and hepatoma cell lines of a single
background. We believe that this study lays the foundation for
personalized in vitro models that can capture genetic variation of
both host and pathogen, whereby iPSCs can be generated from
identified patients with known or unknown genetic defects that
impact infection. In this study we report that hepatocyte-like
cells derived from iPSCs support the entire life cycle of HCV,
including inflammatory responses to infection, but we believe
that in the future patient-derived iHLCs will serve as a model
system to probe the basis of hepatitis viral pathogenesis and that
the model ultimately can be extended to other pathogens and
tissue systems. Such models will advance our understanding of
host–pathogen interactions and help realize the potential of
personalized medicine.
Materials and Methods
iPSC Culture and Hepatocyte-Like Cell Generation. Undifferentiated iPSC were
maintained and differentiated into iHLCs as described (14). In brief, iPSCs
were cultured in monolayer on Matrigel (Becton Dickinson), and directed
differentiation was achieved by sequential exposure to Activin A, bone
morphogenic protein 4, basic FGF, HGF, and oncostatin M (OSM).
HCV Cell-Culture Preparation, Infection, Luciferase Assay, Antiviral Drugs,
and Nonstructural Protein 3/4A Activity Imaging. As described (19), GLuc-
expressing reporter virus Jc1FLAG2(p7-nsGluc2A) stocks were prepared by
electroporating in vitro-transcribed RNA into Huh-7.5 cells, collection of
supernatant, and filter concentration. The 50% tissue culture infectious
dose (TCID50) was determined by titrating on Huh-7.5s to be 10
7 TCID50/mL.
These stocks were diluted 10× in serum-free, OSM-containing medium and
were used to inoculate iHLCs for 24 h. Cultures were washed with serum-
free medium and propagated in OSM-containing medium. Supernatants
were collected daily and frozen at −80 °C for luciferase quantification. To
demonstrate drug-sensitive HCV infection, the HCV NS5B polymerase in-
hibitor 2′ CMA (EC50 = 27 nM on Huh7.5) (21) and the NS3/4A protease in-
hibitor VX-950 (telaprevir) (EC50 = 400 nM on Huh7.5) (21) were added to
culture medium at 50*EC50 and 25*EC50, respectively, at final 0.1% DMSO.
2’CMAwas the gift of. D. Olsen and S. Carroll (Merck Research Laboratories,
West Point, PA) and also was obtained from Carbosynth Limited. VX-950
was obtained from Alembic Limited. Real-time fluorescence reporter of
HCV infection by monitoring NS3/4A protease activity was performed
as described (20). Briefly, lentivirus carrying the reporter was used to
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Fig. 1. Personalized model of HCV infection obtained by infecting iHLCs 
from one donor with HCV from another donor.
HLCs Support the Entire Life Cycle of HCV. To assess HCV replica-
tion in iHLCs, we used a genotype 2a HCV reporter virus 
expressing secreted Gaussia luciferase (GLuc) (19). GLuc signal 
was persistently higher in infected cultures than in uninfected 
(mock) controls (Fig. 3A, Upper) but not in undifferentiated 
iPSCs (Fig. S1); further, initiating daily treatment with either the 
HCV nonstructural protein 5B (NS5B) replicase inhibitor 2′-C-
methyladenosine (2′CMA) or the nonstructural protein 3/4A 
(NS3/4A) protease inhibitor VX-950 (telaprevir) 7 d post-
infection (dpi) rapidly abolished GLuc production (Fig. 3A, 
Upper). Furthermore, consistent with the GLuc assay, quantita-
tive RT-PCR (qRT-PCR) on iHLC lysates 14 dpi showed that 
HCV genomes were significantly more abundant in the absence 
of antivirals (Fig. 3B). In addition, using a real-time fluorescence 
reporter of infection (20), we confirmed HCV protease activity 
in infected iHLCs (Fig. 3C). Together, these results indicate 
ongoing HCV replication in infected iHLCs. To verify that 
infected iHLCs produce infectious virions and thus recapitulate 
the entire viral life cycle, culture supernatants were passaged 13 
dpi onto uninfected Huh-7.5 cells, which are highly permissive to 
HCV and thus allow sensitive detection of infectious virions (21). 
As shown by GLuc production and HCV nonstructural protein 
5A (NS5A) staining (Fig. 3A, Lower), supernatants from infected
analyzed by 2% (wt/vol) agarose gel electrophoresis. Quantitative PCR on
HCV genomes was performed as described (19).
Immunofluorescence Analysis for Hepatic Gene Expression and Host Factor
Expression. iHLCs were fixed in 4% (wt/vol) paraformaldehyde and/or −20 °C
methanol. After washing and blocking in 0.1% donkey serum/0.1% Triton X-
100 in PBS, cells were incubated in primary antibodies overnight at 4 °C:
mouse anti-human albumin (Sigma-Aldrich), rabbit anti–HNF-3β (Santa Cruz
Biotechnology), mouse anti-human CD81 (Becton Dickinson), rabbit anti-
CLDN1 (Invitrogen), rabbit anti-SCARB1 (Novus Biologicals), and mouse anti-
human OCLN (Invitrogen). Secondary antibodies were donkey anti-mouse
DyLight 594, donkey anti-rabbit DyLight 488, donkey anti-mouse DyLight
488-, and donkey anti-rabbit DyLight 594 conjugates. Cells were counter-
stained with Hoechst dye (Invitrogen).
Western Blot for Entry Receptors. Total protein was extracted with radio-
immunoprecipitation assay lysis buffer, and samples were separated by
electrophoresis on 12% (wt/vol) polyacrylamide gels and electrophoreti-
cally transferred to a PVDF membrane (Bio-Rad Laboratories). Blots were
probedwithmouseanti-humanCD81 (Millipore), rabbit anti-SCARB1 (NB110-
57591; Novus Biologicals), rabbit anti-CLDN1 (51-9000; Invitrogen), and rabbit
anti-OCLN (40-4700; Invitrogen), followed by HRP-conjugated secondary
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Fig. 2. iHLCs express known HCV host factors. (A) (Left) Phase image of iHLCs. (Scale bar: 100 μm.) (Right) Immunofluorescence imaging of iHLCs for al-
bumin (red), HNF-3β (green), and DAPI (blue). (Scale bar: 90 μm.) (B) Liver-specific factors in iHLCs. (Upper) MiRNA-122 expression blot and quantification
(Lower Right) for two typical batches of iHLCs (iHCL-A and iHCL-B). Adult human hepatocytes (heps) (15) are included as a reference. (Lower Left)
Quantification of albumin (Alb) and α-1-antitrypsin (A1AT) secretion by iHLCs. Error bars show SD. (C) (Left) Immunofluorescence imaging of iHLCs for
HCV entry factors SRBI (red) and CD81 (green), with DAPI costaining (blue). (Scale bar: 40 μm.) (Right) Immunofluorescence imaging of iHLCs for HCV entry
factors OCLN (red) and CLDN1 (green), with DAPI costaining (blue). (Scale bar: 40 μm.) (D) Western blot for HCV entry receptors CD81, SRBI, CLDN1, and
OCLN in two typical batches of iHLCs (iHLC-A and iHLC-B) in duplicate samples. (E ) Relative expression of HCV host factors (16) by three batches of iPSCs
(iPAC-A, iPAC-B, and iPAC-C) and iHLCs (14). [Host factors are organized by GO biological process terms, including repeats for genes associated with
multiple terms.]
transduce iPSCs. Infection was carried out 5 d later, and protease activity 
was assayed 7 dpi.
Huh-7.5 Culture and Infection Transmission Assay. Huh-7.5 cells were propa-
gated in a DMEM with L-glutamine (Cellgro)-based medium containing 100
U/mL penicillin and 100 μg/mL streptomycin (Cellgro) and 10% (vol/vol) FBS 
(Gibco). To test if infected iHLCs produced infectious virions, iHLCs were 
placed in OSM-containing medium without supplementation with antivirals. 
Supernatants collected 1 d later were used to inoculate Huh-7.5 cells. After 
overnight incubation, cells were washed and placed in Huh-7.5 medium for 
48 h before being washed again. On day 5 postinoculation, supernatants 
were assayed for luciferase as described (19). To assess NS5A antigen ex-
pression, Huh-7.5 cells were fixed in methanol, counterstained with Hoechst 
(Invitrogen), and immunostained with mouse anti-NS5A (9E10) and goat 
anti-mouse Alexa Fluor 594 (Invitrogen).
RT-PCR for Detection of Cytokines and HCV RNA. Total RNA was isolated with 
the RNeasy Plus Mini Kit (Qiagen). First-strand cDNA was synthesized using 
Moloney murine leukemia virus reverse transcriptase (Bio-Rad). Quantitative 
PCR for cytokines was carried out with Taq polymerase and SYBR Green in 
the supplier’s reaction buffer containing 1.5 mM MgCl2 (Bio-Rad). Oligonu-
cleotide primer sequences are available by request (25). Amplicons were
antibodies, and were developed by SuperSignal West Pico substrate
(Thermo Scientific).
miR-122 Analysis. Total RNA was isolated with the miRNeasy Mini Kit
(Qiagen). MiRNAs were polyadenylated by poly(A) polymerase, and cDNA
was synthesized usingmiScript PCR kit (Qiagen). Quantitative real-time PCR
on miR-122 then was performed using Homo sapiens (hsa) miR-122–spe-
cific primer (Qiagen) and normalized to RNA, U6B small nuclear (RNU6B)
(Qiagen). Standard curves were performed to obtain absolute levels with
synthetic miR-122 (Dharmacon).
Albumin and α-1-Antitrypsin ELISA. Spent medium was stored at −20 °C. α-1-
Antitrypsin and albumin media concentrations were measured using sand-
wich ELISA technique with HRP detection (Bethyl Laboratories) and 3,3′,5,5′-
tetramethylbenzidine (Thermo Scientific) as a substrate.
Microarray Analysis and Host Factor Expression. Microarray analysis was per-
formed as described (14). Microarray profiles on iHLCs (http://www.ncbi.nlm.
nih.gov/geo/, accession no. GSE14897) were analyzed using gene set en-
richment analysis v. 2.0 with a list of previously identified HCV host factors
(16). Enriched genes were determined by random permutation of gene sets
and a P value < 0.05. Gene ontology (GO) terms and gene associations were
obtained using Gene Set Analysis Toolkit v. 2. Statistical analysis was per-
formed using a hypergeometric distribution to identify terms enriched with
two genes and a P value <0.05 and then connected in a tree hierarchy (26).
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Fig. 3. iPSC-derived iHLCs as a model for hepatitis C. (A) iHLC cultures were infected with HCV reporter virus expressing secreted GLuc (n = 18) or were
mock infected (n = 6) and subsequently were sampled and washed daily. After 7 d (solid gray arrow), infected iHLCs were treated with the NS5B poly-
merase inhibitor 2′CMA (n = 6), NS3/4A protease inhibitor VX-950 (n = 6), or vehicle DMSO (n = 6). Drug treatment was discontinued 12 dpi, and
supernatants collected after an additional day of culture were assayed for the presence of infectious virus by passage onto Huh-7.5 cells. Medium from
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was statistically significant: *P < 0.05, ***P < 0.001 (one-way ANOVA with Tukey’s post test). RLU, relative light units. (Lower Left) GLuc secretion by Huh-
7.5s after passage of iHLC supernatants. DMSO vs. mock was statistically significant: ***P < 0.001 (one-way ANOVA with Tukey’s post test). (Lower Right)
NS5A staining of infected Huh-7.5 cells post passage. (Scale bar: 50 μm.) (B) iHLCs were lysed 14 dpi. Copies of HCV RNA in lysates were quantified by qRT-
PCR. DMSO vs. 2′CMA was statistically significant: ***P < 0.001 (one-way ANOVA after log transformation with Tukey’s post test). (C) NS3/4A activity
imaging of HCV-infected iHLCs (20). White lines surround uninfected cells; red line surrounds an infected cell. (Scale bar, 25 μm.) Data in A–C are means;
error bars show SD.
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